Author(s): Maria-Victoria Mateos, Philippe Moreau, James R. Berenson, et al. Abstract: S849 Session topic: 14. Myeloma and other monoclonal gammopathies – Clinical Background Twice-weekly carfilzomib (K) at 20/27 mg/m2 is approved for the treatment of RRMM. To develop a more convenient K regimen, once-weekly K plus dexamethasone (d) was assessed in the...
Pro zobrazení tohoto obsahu je třeba být přihlášen.